VistaGen Therapeutics IncOTCQB:VSTA
Symbol Lookup
Refresh
Recent News»
0 New Today| Company | Market Cap | P/E Ratio (TTM) | EPS Growth (5yr) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SANUWAVE Health Inc SNWV | 15.2M | -- | -- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Ghana Gold Corp GGCO | 20.0M | -- | -- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Islet Sciences Inc ISLT | 16.8M | -- | -- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Manhattan Scientifics Inc MHTX | 20.6M | -- | -- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cadus Corp KDUS | 18.1M | -- | -- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Data delayed 15 minutes. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Company Information
VistaGen Therapeutics, Inc. (Vistagen), fomerly Excaliber Enterprises, Ltd., is a biotechnology company. The Company's integrated stem cell biology platform, Human Clinical Trials in a Test Tube, is designed to provide an early indication, or prediction, of the cardiac toxicity of drug candidates before they are ever tested in humans. The Company's products include CardioSafe 3D, LiverSafe 3D and AV-101. CardioSafe 3D is a three-dimensional biological assay (screening) system that uses human heart cells to screen for cardiac toxicity. On May 11, 2011, Vistagen Therapeutics, Inc., a California corporation, merged with Excaliber Merger Subsidiary, Inc., which is a subsidiary of the Company. Cato Holding Company acquired its Vistagen shares and warrants in a number of transactions between August 30, 2001 and May 10, 2011.
| Headquarters | Suite #8, 384 Oyster Point Blvd SOUTH SAN FRANCISCO, CA, United States 94080 |
|---|---|
| Phone | 650-244-9990 |
| Fax | 888-482-2602 |
EXECUTIVE OFFICERS
| President, Chief Scientific Officer, Director | H. Ralph Snodgrass |
|---|---|
| Chief Executive Officer, Director | Shawn Singh |
| Chief Financial Officer | Jerrold Dotson |
| Vice President - Corporate Development, Secretary | A. Franklin Rice |
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
Open a New Account, or Login if you're a client.
(GAAP)*
| Market Cap | $17.1M | Beta | -- |
|---|---|---|---|
| Revenue (TTM) | $669.3K | EPS | $-1.09 |
| Shares Out. | 20.1M | Book Value | $-0.34 |
| VistaGen Therapeutics Inc does not pay a dividend. | P/E | -- | |
| Price/Sales (TTM) | 25.5 | ||
| P/Cash Flow (TTM) | -- | ||
| Operating Margin | -1,739.88% | ||
*GAAP = prior to non-GAAP analyst adjusted earnings.
(Non-GAAP)*
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
